ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

The Past, Present and Future of the Total Artificial Heart

The Texas Heart Institute

W. Cohn, O. Frazier

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Donation After Cardiac Death: A New Paradigm for Organ Donation in H…

Cedars Sinai

P. Catarino

High-Risk Cardiac Surgery and Pre-Op Optimization with Impella Base …

St. Louis Shock & Heart Failure Symposium 2022

J. Leidenfrost

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Use of MCS in Management of Acute Post-MI VSD

Houston Shock Symposium

D. Ramini

Heart Failure Case Presentations

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

B. Greenberg, G. Fonarow, N. Wettersten, M. Rosa Costanzo

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

Cardiogenic Shock: Should IABP or PVADs Be Used in Cardiogenic Shock?

American Heart & Vascular Institute

M. Ansari